Immunome (IMNM) Expected to Announce Quarterly Earnings on Thursday

Immunome (NASDAQ:IMNM) is expected to release its earnings data before the market opens on Thursday, March 27th. Analysts expect Immunome to post earnings of ($0.72) per share and revenue of $3.16 million for the quarter.

Immunome (NASDAQ:IMNM) last released its earnings results on Wednesday, March 19th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. On average, analysts expect Immunome to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Immunome Price Performance

Immunome stock opened at $8.57 on Thursday. Immunome has a one year low of $8.30 and a one year high of $26.70. The stock has a market capitalization of $683.69 million, a PE ratio of -1.06 and a beta of 1.93. The business’s fifty day moving average is $9.84 and its 200 day moving average is $11.64.

Insider Buying and Selling at Immunome

In other news, CEO Clay B. Siegall bought 150,000 shares of the stock in a transaction on Friday, January 31st. The shares were bought at an average price of $7.75 per share, with a total value of $1,162,500.00. Following the completion of the acquisition, the chief executive officer now owns 669,636 shares in the company, valued at $5,189,679. The trade was a 28.87 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 8.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Wedbush reaffirmed an “outperform” rating and set a $33.00 price objective on shares of Immunome in a research report on Monday, March 10th. Lifesci Capital assumed coverage on Immunome in a research report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 price objective on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $27.17.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.